These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 32430484

  • 1. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
    Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D.
    Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K, Zhang Z, Bai Z, Ma X, Guo W, Wang Y.
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [Abstract] [Full Text] [Related]

  • 3. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
    Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR.
    Cancer Res; 2009 Jun 01; 69(11):4567-72. PubMed ID: 19487279
    [Abstract] [Full Text] [Related]

  • 4. Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.
    Brockschmidt C, Hirner H, Huber N, Eismann T, Hillenbrand A, Giamas G, Radunsky B, Ammerpohl O, Bohm B, Henne-Bruns D, Kalthoff H, Leithäuser F, Trauzold A, Knippschild U.
    Gut; 2008 Jun 01; 57(6):799-806. PubMed ID: 18203806
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA.
    Clin Cancer Res; 2006 Apr 15; 12(8):2492-7. PubMed ID: 16638857
    [Abstract] [Full Text] [Related]

  • 6. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
    Kerr M, Scott HE, Groselj B, Stratford MR, Karaszi K, Sharma NL, Kiltie AE.
    Clin Cancer Res; 2014 Nov 01; 20(21):5435-45. PubMed ID: 25224279
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M.
    Anticancer Res; 2008 Nov 01; 28(4B):2205-12. PubMed ID: 18751396
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M.
    Clin Cancer Res; 2004 May 01; 10(9):2936-43. PubMed ID: 15131028
    [Abstract] [Full Text] [Related]

  • 15. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S, Ueda T, Komuro A, Amano H, Honda M, Kawazu M, Okada H.
    Mol Cancer Res; 2023 May 01; 21(5):444-457. PubMed ID: 36757299
    [Abstract] [Full Text] [Related]

  • 16. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F, Huang M, Chen Q, Niu Y, Hu Y, Hu P, Chen D, He C, Huang K, Zeng Z, Tang J, Wang F, Zhao Y, Wang C, Zhao G.
    Cancer Res; 2021 Nov 15; 81(22):5678-5691. PubMed ID: 34593522
    [Abstract] [Full Text] [Related]

  • 17. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
    Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, Koca C, Yadav VR, Tong Z, Gelovani JG, Guha S, Krishnan S, Aggarwal BB.
    Cancer Res; 2010 Nov 01; 70(21):8695-705. PubMed ID: 20864511
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
    Dash S, Ueda T, Komuro A, Honda M, Sugisawa R, Okada H.
    Cell Death Dis; 2024 Feb 12; 15(2):131. PubMed ID: 38346958
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
    Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES.
    Oncogene; 2020 Feb 12; 39(9):1831-1845. PubMed ID: 31745297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.